Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × acalabrutinib × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 50 Other hematologic neoplasm 26 Thoracic 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 Classical hematology 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 276 Radiotherapy 122 pembrolizumab 117 Cetuximab 116 Docetaxel 110 Carboplatin 106 Paclitaxel 86 Fluorouracil 85 Radiotherapy, Intensity-Modulated 84 Nivolumab 51 Gemcitabine 45 toripalimab 41 Radiation 40 Capecitabine 36 Drug Therapy 33 Magnetic Resonance Spectroscopy 29 camrelizumab 28 Surgical Procedures, Operative 28 apatinib 26 130-nm albumin-bound paclitaxel 25 tislelizumab 23 Bevacizumab 23 durvalumab 22 Chemoradiotherapy 22 Specimen Handling 21 nimotuzumab 20 Biopsy 19 Albumin-Bound Paclitaxel 19 sintilimab 18 lenvatinib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02454179 2019-09-12

KEYNOTE147

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡